Androgen receptor: structure, role in prostate cancer and drug discovery
M-H. Tan, Jun Li, H. Eric Xu et al. · Acta Pharmacologica Sinica · 2014
Androgens and androgen receptors (AR) play a pivotal role in expression of the male phenotype. Several diseases, such as androgen insensitivity syndrome (AIS) and prostate cancer, are associated with alterations in AR functions. Indeed, androgen blockade by drugs that prevent the production of androgens and/or block the action of the AR inhibits prostate cancer growth. However, resistance to these drugs often occurs after 2-3 years as the patients develop castration-resistant prostate cancer (CRPC). In CRPC, a functional AR remains a key regulator. Early studies focused on the functional domains of the AR and its crucial role in the pathology. The elucidation of the structures of the AR DNA binding domain (DBD) and ligand binding domain (LBD) provides a new framework for understanding the functions of this receptor and leads to the development of rational drug design for the treatment of prostate cancer. An overview of androgen receptor structure and activity, its actions in prostate cancer, and how structural information and high-throughput screening have been or can be used for drug discovery are provided herein.
Cited by 943 works. doi:10.1038/aps.2014.18 Open-access PDF
Authors
References
- Cancer statistics, 2013
- The nuclear receptor superfamily: The second decade
- Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
- Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
- The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy